ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects. Issue 5 (29th January 2019)

• Record Type: Journal Article
• Authors: Brivio, Erica; Zwaan, C. Michel
• Is Part Of: Pediatric blood & cancer. Volume 66:Issue 5(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-01-29
• Subjects: ALK inhibitors -- ceritinib -- inflammatory myofibroblastic tumor -- pediatric oncology; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.27645
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: There is an increasing interest for anaplastic lymphoma kinase (ALK) inhibitors in pediatric oncology for specific entities such as ALK‐driven inflammatory myofibroblastic tumor (IMT). IMT treatment can be challenging due to localization of the tumor and in rare cases of metastasis. When standard surgical treatment is not feasible, ALK inhibitors may play an important role, as recently reported for the first‐generation ALK inhibitors (crizotinib). However, data on the second‐generation ALK inhibitors are limited. We report two emblematic cases of IMT in pediatric patients, treated with the second‐generation ALK inhibitor ceritinib in the context of a clinical trial (NCT01742286).